SEARCH

SEARCH BY CITATION

References

  • 1
    Floistrup H, Swartz JThe Parsifal Study G. et al. Allergic disease and sensitization in Steiner school children. J Allergy Clin Immunol 2006; 117:5966.
  • 2
    Kay A Allergy and allergic diseases. Oxford, UK: Blackwell Science, 2008.
  • 3
    Kulig M, Bergmann R, Klettke U, Wahn V, Tacke U, Wahn U. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol 1999; 103:11739.
  • 4
    Niederberger V, Niggemann B, Kraft D, Spitzauer S, Valenta R. Evolution of IgM, IgE and IgG(1-4)antibody responses in early childhood monitored with recombinant allergen components: implications for class switch mechanisms. Eur J Immunol 2002; 32:57684.
  • 5
    Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol 2007; 7:93104.
  • 6
    Macfarlane AJ, Kon OM, Smith SJ et al. Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in late-phase allergic reactions in the lung and skin. J Allergy Clin Immunol 2000; 105:99107.
  • 7
    Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006; 117:127784.
  • 8
    Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999; 189:188594.
  • 9
    Oldfield WL, Kay AB, Larché M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001; 167:17349.
  • 10
    Campana R, Mothes N, Rauter I et al. Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments. J Allergy Clin Immunol 2008; 121:52830.e1.
  • 11
    Hansel TT, Barnes PJ New drugs for asthma, allergy and COPD. Basel, CH: Karger, 2001.
  • 12
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:55862.
  • 13
    Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:46875.
  • 14
    Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:31925.
  • 15
    Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:76171.
  • 16
    Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002; 2:44653.
  • 17
    Valenta R, Ball T, Focke M et al. Immunotherapy of allergic disease. Adv Immunol 2004; 82:10553.
  • 18
    Van Neerven RJ, Knol EF, Ejrnaes A, Würtzen PA. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int Arch Allergy Immunol 2006; 141:11929.
  • 19
    Van Neerven RJ, Wikborg T, Lund G et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163:294452.
  • 20
    Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003; 112:91522.
  • 21
    Mothes N, Heinzkill M, Drachenberg KJ et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33:1198208.
  • 22
    Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004; 101 (Suppl. 2):1467782.
  • 23
    Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:144555.
  • 24
    Larche M. Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr Opin Immunol 2006; 18:74550.
  • 25
    Schwartz HJ. Problems with skin testing in patients with allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 1995; 75:5335.
  • 26
    Van Der Veen MJ, Mulder M, Witteman AM et al. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens. J Allergy Clin Immunol 1996; 98:102834.
  • 27
    Rosenbaum MR, Esch RE, Schwartzman RM. Effects of mold proteases on the biological activity of allergenic pollen extracts. Am J Vet Res 1996; 57:144752.
  • 28
    Akkerdaas JH, Wensing M, Knulst AC et al. How accurate and safe is the diagnosis of hazelnut allergy by means of commercial skin prick test reagents? Int Arch Allergy Immunol 2003; 132:13240.
  • 29
    Trivedi B, Valerio C, Slater JE. Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol 2003; 111:77783.
  • 30
    Valerio CR, Murray P, Arlian LG, Slater JE. Bacterial 16S ribosomal DNA in house dust mite cultures. J Allergy Clin Immunol 2005; 116:1296300.
  • 31
    Focke M, Marth K, Flicker S, Valenta R. Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy 2008; 38:14008.
  • 32
    Focke M, Marth K, Valenta R. Molecular composition and biological activity of commercial birch pollen allergen extracts. Eur J Clin Invest 2009; 39:42936.
  • 33
    Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol 2004; 113:112936.
  • 34
    Malling HJ. Sublingual immunotherapy: efficacy–methodology and outcome of clinical trials. Allergy 2006; 61 (Suppl. 81):248.
  • 35
    Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin Exp Allergy 2006; 36:25460.
  • 36
    Rezvani M, Bernstein DI. Anaphylactic reactions during immunotherapy. Immunol Allergy Clin N Am 2007; 27:295307.
  • 37
    Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006; 61:1235.
  • 38
    Antico M, Pagani, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006; 61:123637.
  • 39
    Agostinis F, Foglia C, Landi M et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy 2008; 63:16379.
  • 40
    Esch RE, Bush RK, Peden D, Lockey RF. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol 2008; 100:47581.
  • 41
    Wahn U, Tabar A, Kuna P et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123:1606.
  • 42
    Arvidsson MB, Lowhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002; 109:77783.
  • 43
    Gadermaier E, Flicker S, Aberer W et al. Dissection of the antibody responses induces by subcutaneous injection immunotherapy with aluminium hydroxide-absorbed birch and Fagales pollen extracts. Int Arch Allergy Immunol 2010; 151:1727.
  • 44
    Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:8029.
  • 45
    Van Ree R, Antonicelli L, Akkerdaas JH, Garritani MS, Aalberse RC, Bonifazi F. Possible induction of food allergy during mite immunotherapy. Allergy 1996; 51:10813.
  • 46
    Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002; 57:42330.
  • 47
    Van Hage-Hamsten M, Valenta R. Specific immunotherapy – the induction of new IgE-specificities? Allergy 2002; 57:3758.
  • 48
    Pastorello EA, Incorvaia C, Gerosa A, Vassellatti D, Italia M, Pravettoni V. Allergen specific IgG subclass antibody response in hyposensitization with Dermatophagoides pteronyssinus extract. N Engl Reg Allergy Proc 1987; 8:41721.
  • 49
    McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990; 86:52131.
  • 50
    Ball T, Sperr WR, Valent P et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999; 29:202636.
  • 51
    Ball T, Fuchs T, Sperr WR et al. B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J 1999; 13:127790.
  • 52
    Rossi RE, Monasterolo G. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Int Arch Allergy Immunol 2004; 135:4453.
  • 53
    Pauli G, Larsen TH, Rak S et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122:95160.
  • 54
    Didier A, Melac M, Montagut A, Lhéritier-Barrand M, Tabar A, Worm M. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy 2009; 64:16671.
  • 55
    Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005; 35:56571.
  • 56
    Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:412.
  • 57
    Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61:116272.
  • 58
    Nettis E, Colanardi MC, Soccio AL et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol 2007; 156:67481.
  • 59
    Alvarez-Cuesta E, Berges-Gimeno P, González-Mancebo E, Fernández-Caldas E, Cuesta-Herranz J, Casanovas M. Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study. Allergy 2007; 62:8107.
  • 60
    Kazemi-Shirazi L, Niederberger V, Linhart B, Lidholm J, Kraft D, Valenta R. Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy. Int Arch Allergy Immunol 2002; 127:25968.
  • 61
    Pittner G, Vrtala S, Thomas WR et al. Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy 2004; 34:597603.
  • 62
    Valenta R, Twaroch T, Swoboda I. Component-resolved diagnosis to optimize allergen-specific immunotherapy in the Mediterranean area. J Invest Allergol Clin Immunol 2007; 17 (Suppl. 1):3640.
  • 63
    Hiller R, Laffer S, Harwanegg C et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J 2002; 16:4146.
  • 64
    Niederberger V, Ring J, Rakoski J et al. Antigens drive memory IgE responses in human allergy via the nasal mucosa. Int Arch Allergy Immunol 2007; 142:13344.
  • 65
    Yamaguchi M, Sayama K, Yano K et al. IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J Immunol 1999; 162:545565.
  • 66
    Saini SS, Klion AD, Holland SM, Hamilton RG, Bochner BS, Macglashan DW Jr The relationship between serum IgE and surface levels of FcepsilonR on human leukocytes in various diseases: correlation of expression with FcepsilonRI on basophils but not on monocytes or eosinophils. J Allergy Clin Immunol 2000; 106:51420.
  • 67
    Katoh N, Kraft S, Wessendorf JH, Bieber T. The high-affinity IgE receptor (FcepsilonRI) blocks apoptosis in normal human monocytes. J Clin Invest 2000; 105:18390.
  • 68
    Kalesnikoff J, Huber M, Lam V et al. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 2001; 14:80111.
  • 69
    Marsh DG, Lichtenstein LM, Campbell DH. Studies on “allergoids” prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 1970; 18:70522.
  • 70
    Bousquet J, Maasch HJ, Hejjaoui A et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989; 84:54656.
  • 71
    Haselden BM, Kay AB, Larché M. Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol 2000; 122:22937.
  • 72
    Purohit A, Niederberger V, Kronqvist M et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008; 38:151425.
  • 73
    Sledge R. Treatment of alum-precipitated pollen. US Naval Med Bull 1938; 36:18.
  • 74
    Zoss A, Koch CA, Hirose R. Alum-Ragweed precipitate: preparation and clinical investigation; preliminary report. J Allergy Clin Immunol 1939; 8:29.
  • 75
    Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001; 126:1359.
  • 76
    Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56:498505.
  • 77
    Marsh DG, Norman PS, Roebber M, Lichtenstein LM. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Immunol 1981; 68:44959.
  • 78
    Norman PS, Lichtenstein LM, Kagey-Sobotka A, Marsh DG. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol 1982; 70:24860.
  • 79
    Attallah NA, Sehon AH. Isolation of haptenic material from ragweed pollen. Immunochemistry 1969; 6:60919.
  • 80
    Malley A, Begley D, Forsham A. Chemical modification of timothy grass pollen antigen B – I. Loss of antibody binding properties. Mol Immunol 1979; 16:92934.
  • 81
    Litwin A, Pesce AJ, Fischer T, Michael M, Michael JG. Regulation of the human immune response to ragweed pollen by immunotherapy. A controlled trial comparing the effect of immunosuppressive peptic fragments of short ragweed with standard treatment. Clin Exp Allergy 1991; 21:45765.
  • 82
    Lee WY, Sehon AH. Abrogation of reaginic antibodies with modified allergens. Nature 1977; 267:6189.
  • 83
    Mosbech H, Dreborg S, Pahlman I, Stahl Skov P, Steringer I, Weeke B. Modification of house dust mite allergens by monomethoxypolyethylene glycol. Allergenicity measured by in vitro and in vivo methods. Int Arch Allergy Appl Immunol 1988; 85:1459.
  • 84
    Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005; 60:8017.
  • 85
    Valenta R, Kraft D. Recombinant allergens for diagnosis and therapy of allergic diseases. Curr Opin Immunol 1995; 7:7516.
  • 86
    Hoyne GF, O'Hehir RE, Wraith DC, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993; 178:17838.
  • 87
    Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA 1993; 90:760812.
  • 88
    Norman PS, Ohman JL Jr, Long AA et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154:16238.
  • 89
    Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996; 8:193745.
  • 90
    Pene J, Desroches A, Paradis L et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 1998; 102:5718.
  • 91
    Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999; 93:22231.
  • 92
    Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360:4753.
  • 93
    Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005; 60:126974.
  • 94
    Fellrath JM, Kettner A, Dufour N et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003; 111:85461.
  • 95
    Mueller U, Akdis CA, Fricker M et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101:74754.
  • 96
    Raz E, Tighe H, Sato Y et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996; 93:51415.
  • 97
    Hsu CH, Chua KY, Tao MH et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996; 2:5404.
  • 98
    Slater JE, Paupore E, Zhang YT, Colberg-Poley AM. The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J Allergy Clin Immunol 1998; 102:46975.
  • 99
    Tighe H, Takabayashi K, Schwartz D et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000; 106:12434.
  • 100
    Bohle B, Breitwieser A, Zwolfer B et al. A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J Immunol 2004; 172:66428.
  • 101
    Tulic MK, Fiset PO, Christodoulopoulos P et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004; 113:23541.
  • 102
    Linhart B, Valenta R. Molecular design of allergy vaccines. Curr Opin Immunol 2005; 17:64655.
  • 103
    Reisinger J, Horak F, Pauli G et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005; 116:34754.
  • 104
    Kahlert H, Suck R, Weber B et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol 2008; 145:193206.
  • 105
    Klimek L, Bachert C, Doemer C, Meyer H, Narkus A. Specific immunotherapy with recombinant birch pollen allergen Bet v 1-FV is clinically efficious. Allergy Clin Immunol Int 2005; (Suppl. 1):15.
  • 106
    Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007; 119:82630.
  • 107
    Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116:60813.
  • 108
    Linhart B, Jahn-Schmid B, Verdino P et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 2002; 16:13013.
  • 109
    King TP, Jim SY, Monsalve RI, Kagey-Sobotka A, Lichtenstein LM, Spangfort MD. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J Immunol 2001; 166:605765.
  • 110
    Linhart B, Valenta R. Vaccine engineering improved by hybrid technology. Int Arch Allergy Immunol 2004; 134:32431.
  • 111
    Linhart B, Hartl A, Jahn-Schmid B et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 2005; 115:10106.
  • 112
    Linhart B, Mothes-Luksch N, Vrtala S, Kneidinger M, Valent P, Valenta R. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biol Chem 2008; 389:92533.
  • 113
    Metz-Favre C, Linhart B, Focke-Tejkl M et al. Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule. J Allergy Clin Immunol 2007; 120:31521.
  • 114
    Katz DH, Paul WE, Goidl EA, Benacerraf B. Carrier function in anti-hapten immune responses. I. Enhancement of primary and secondary anti-hapten antibody responses by carrier preimmunization. J Exp Med 1970; 132:26182.
  • 115
    Paul WE, Katz DH, Goidl EA, Benacerraf B. Carrier function in anti-hapten immune responses. II. Specific properties of carrier cells capable of enhancing anti-hapten antibody responses. J Exp Med 1970; 132:28399.
  • 116
    Focke M, Mahler V, Ball T et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 2001; 15:20424.
  • 117
    Focke M, Linhart B, Hartl A et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 2004; 34:152533.
  • 118
    Musselli C, Livingston PO, Ragupathi G. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. J Cancer Res Clin Oncol 2001; 127:R206.
  • 119
    Demoly P, Persi L, Dhivert H, Delire M, Bousquet J. Immunotherapy with keyhole limpet hemocyanin-conjugated decapeptide vaccine in cypress pollen allergy. Clin Exp Allergy 2002; 32:10716.
  • 120
    Edlmayr J, Niespodziana K, Linhart B et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a non-allergenic peptide of the major timothy grass pollen allergen, Phl p 1. J Immunol 2009; 182:6298306.
  • 121
    Kündig TM, Senti G, Schnetzler G et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006; 117:14706.